Zhejiang Jiuzhou Pharm Co Ltd
Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecule, drug product, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, and … Read more
Zhejiang Jiuzhou Pharm Co Ltd (603456) - Total Liabilities
Latest total liabilities as of June 2025: CN¥2.18 Billion CNY
Based on the latest financial reports, Zhejiang Jiuzhou Pharm Co Ltd (603456) has total liabilities worth CN¥2.18 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Jiuzhou Pharm Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Zhejiang Jiuzhou Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Jiuzhou Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Jiuzhou Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Everi Holdings Inc
NYSE:EVRI
|
USA | $1.94 Billion |
|
Beijing Qianjing Landscape Co
SHG:603778
|
China | CN¥2.54 Billion |
|
Carel Industries S.p.A.
LSE:0YQA
|
UK | €398.58 Million |
|
Willdan Group Inc
NASDAQ:WLDN
|
USA | $224.83 Million |
|
The South Indian Bank Limited
NSE:SOUTHBANK
|
India | ₹1.27 Trillion |
|
NPK International Inc.
NYSE:NPKI
|
USA | $90.60 Million |
|
Evotec SE
PINK:EVOTF
|
USA | $972.56 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Zhejiang Jiuzhou Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Jiuzhou Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Jiuzhou Pharm Co Ltd (2011–2024)
The table below shows the annual total liabilities of Zhejiang Jiuzhou Pharm Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.52 Billion | +8.57% |
| 2023-12-31 | CN¥2.32 Billion | -8.77% |
| 2022-12-31 | CN¥2.54 Billion | +3.19% |
| 2021-12-31 | CN¥2.46 Billion | +28.59% |
| 2020-12-31 | CN¥1.92 Billion | +5.73% |
| 2019-12-31 | CN¥1.81 Billion | +243.94% |
| 2018-12-31 | CN¥526.81 Million | +14.08% |
| 2017-12-31 | CN¥461.77 Million | +6.89% |
| 2016-12-31 | CN¥432.01 Million | -47.28% |
| 2015-12-31 | CN¥819.46 Million | +31.12% |
| 2014-12-31 | CN¥624.98 Million | -23.25% |
| 2013-12-31 | CN¥814.26 Million | +9.11% |
| 2012-12-31 | CN¥746.26 Million | +14.28% |
| 2011-12-31 | CN¥653.04 Million | -- |